: 1
Oral BPC-157 shows potential as a gut-targeted therapy, but its effectiveness in humans is still experimental, and outcomes may vary depending on formulation, dose, and individual digestive conditions
What's more, some supplements aren't research-backed, evidence-informed, or third-party tested
Additionally, combining it with low-level peptides like pal-tetrapeptide-7 enhances matrix signaling without irritation
They can modulate immune responses
In December 2024, the FDA issued warning letters to several companies selling peptide products online, citing compounds such as retatrutide along with semaglutide and tirzepatide being marketed under research use only disclaimers while appearing to target consumers seeking weight-loss or performance benefits